BRANY (Biomedical Research Alliance of New York) has announced it has been designated a Quintiles Prime Site. The designation will advance BRANY’s participation in clinical trials by providing improved access to new industry-sponsored clinical trials.
BRANY joins other select organizations that have received the same designation from Quintiles across the USA, Europe, Africa and Asia. BRANY is committed to excellence in the conduct of clinical research, and the company supports Quintiles’ vision to bring people and knowledge together for a healthier world. BRANY’s network of highly qualified and experienced researchers and track record in working with community and academic study sites will accelerate the development of new therapies.
“BRANY is committed to excellence in clinical research and improving patient care , says Kimberly Irvine, Executive Vice President of Operations at BRANY. “This alliance will provide our leading investigators and hospitals with significant opportunities to access industry-sponsored clinical trials. We are excited to be working with Quintiles to bring new clinical trials to our sites and patients.”
BRANY’s Smart Start 60 increases efficiencies and sustainability among their community and academic study sites to expedite clinical research timelines. These efficiencies translate to real-life benefits as clinical trials are concluded on or ahead of schedule to advance treatments for unmet medical needs in a cost-effective way that does not jeopardize the quality standards of the of research.
“We have been working with BRANY for 14 years and are continuously impressed with the calibre of their investigator network and the quality of their research,” said Lindy Jones, Senior Vice President, Integrated Site Services, Quintiles. “BRANY consistently sets and meets aggressive start-up timelines. They are able to conduct studies in both the hospital and community settingbroadening opportunities for patients to participate in studies. We welcomeBRANY as the newest Prime Site and look forward to continued success together.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.